Migraine Market
information, by types (Episodic and Chronic), by treatment type (Preventive and
Abortive), by drug class (Triptans, Ergots, and Others) - Global Forecast to
2022
Market Analysis
The global Migraine
Market is anticipated to grow at an impressive CAGR
between 2013-2022, states the latest Market Research Future (MRFR) report.
Migraine is basically a neurological condition which can result in multiple
symptoms. It is characterized by a debilitating, intense headache. Often
migraine runs in families and can affect every age group. Sensitivity to sound
and light, difficulty speaking, tingling or numbness, vomiting, and nausea are
common symptoms of migraines.
Migraine may begin during childhood, or it may not occur until
early adulthood. Generally, women are more likely to suffer from migraines than
men. Migraine with aura or classic migraines and without aura or common
migraine are the two common categories of migraine. The pain mostly affects the
area of the forehead, is usually on one side of the head, yet may shift, or
occur on both sides of the head.
Numerous factors are pushing the growth of the market such as
growing awareness regarding the prevention and also treatment of migraine,
rising healthcare expenditure, launch and FDA approval of new migraine drugs,
rising cigarette consumption, increasing intake of hormonal medications,
lifestyle changes, rising disease prevalence, and stressed lifestyle.
Additional factors propelling the growth of the migraine market include
accelerating economic growth, rising prevalence of migraine, increasing female
population, demand for hormonal medications, high unmet needs, and launch of
calcitonin gene-related peptide (CGRP).
On the contrary, different side effects from migraine drugs,
stringent government regulations, regulatory challenges, scarcity of proper
diagnosis, rising preference of alternative therapies, and increasing
investment in drug R&D are factors that may restrict the migraine market
growth during the forecast period.
Market Segmentation
The global migraine market has been segmented in terms of drug
class, types, and treatment types.
By types, the migraine market is segmented into chronic as well
as episodic. Of these, the episodic segment will lead the market during the
forecast period owing to its increasing prevalence.
By treatment types, the migraine market is segmented into
abortive and preventive. Of these, the abortive segment will dominate the
market during the forecast period for the ease of self-administration in those
with migraines accompanied by vomiting and nausea.
By drug class, the migraine market is segmented into ergots,
triptans, and others. Of these, triptans will have maximum share in the market
during the forecast period.
Browse
Complete Report :https://www.marketresearchfuture.com/reports/migraine-market-2381
Regional Analysis
The global migraine market report is geographically distributed
across the following key regions: North America, Europe, the Asia Pacific
(APAC), and the Rest of the World (RoW). Among these, North America will have
the lion’s share in the market during the forecast period. Various factors
propelling the growth of the migraine market in the region include the launch
of CGRP based therapies, adoption of novel therapeutics, huge target
population, especially in the US, increasing R&D activities in the region,
and increasing incidence of migraine. The US is the major contributor in the
region.
The migraine market in the APAC region will have favorable
growth during the forecast period. Various factors propelling the growth of the
migraine market in the region include increasing healthcare expenditure,
growing disease awareness, huge underserved population, and low-cost production
of drugs.
The migraine market in Europe will have a notable growth during
the forecast period for rising stress levels, changing lifestyles, and rising
incidence of hormonal imbalance.
The migraine market in the RoW will have stable growth during
the forecast period.
Key Players
Notable players
profiled in the global migraine market report include Pfizer, Inc., Eisai Inc.,
Impax Laboratories, Eli Lilly and Company, Abbott Laboratories, Allegan,
Luitpold Pharmaceuticals, Klaria, Johnson and Johnson, Kowa Pharmaceuticals
America, GlaxoSmithKline plc., OptiNose, Meda, AstraZeneca plc, Merck, and
others. Key players have used specific strategies to stay head and shoulders
above others in the competition, such as collaborations, expansions, mergers
and acquisitions, research and development activities, new product launches,
and more.
Industry News
October 2019: Eli Lilly’s Reyvow has received FDA approval to
treat acute migraines. It is the only and foremost medicine that has received
approval from the FDA to treat acute migraines.
No comments:
Post a Comment